For this purpose, both the beta-emitter Lu-177 and the alpha-emitter Ac-225 are coupled to PSMA-617 or PSMA-I&T targeting metastatic prostate cancer cells (6, 7).However, these therapies are not promoted by the China Food and Drug Administration (CFDA). Here, FOLH1 is linked to prostate carcinoma.